Short Interest in Astellas Pharma Inc. (OTCMKTS:ALPMY) Increases By 201.3%

Astellas Pharma Inc. (OTCMKTS:ALPMY) was the target of a significant growth in short interest in June. As of June 30th, there was short interest totaling 49,919 shares, a growth of 201.3% from the June 15th total of 16,568 shares. Based on an average daily trading volume, of 468,461 shares, the days-to-cover ratio is currently 0.1 days. Currently, 0.0% of the shares of the stock are short sold.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the company. Zacks Research raised Astellas Pharma from a “hold” rating to a “strong-buy” rating in a report on Tuesday, June 23rd. Jefferies Financial Group raised shares of Astellas Pharma from a “hold” rating to a “strong-buy” rating in a report on Tuesday, March 24th. Two equities research analysts have rated the stock with a Strong Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy”.

Astellas Pharma Price Performance

Shares of OTCMKTS:ALPMY opened at $13.25 on Monday. Astellas Pharma has a one year low of $9.46 and a one year high of $17.35. The stock has a fifty day moving average of $13.76 and a 200-day moving average of $14.65. The company has a market capitalization of $23.98 billion, a PE ratio of 12.34 and a beta of 0.07. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.90 and a current ratio of 1.17.

Astellas Pharma (OTCMKTS:ALPMY) last announced its earnings results on Monday, April 27th. The company reported $0.33 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.19 by $0.14. Astellas Pharma had a return on equity of 23.54% and a net margin of 13.66%.The company had revenue of $3.38 billion for the quarter, compared to analyst estimates of $3.28 billion. As a group, equities analysts anticipate that Astellas Pharma will post 1.25 EPS for the current fiscal year.

About Astellas Pharma

Astellas Pharma Inc is a Tokyo-based, global pharmaceutical company traded in the United States as an American Depositary Receipt on the OTC Markets under the symbol ALPMY. The company focuses on discovering, developing and marketing prescription medicines in key therapeutic areas, including oncology, urology, immunology, neuroscience and cardiovascular/metabolic diseases. Astellas seeks to bring innovative treatments to market by combining internal research capabilities with external partnerships and collaborative agreements around the world.

Core products in Astellas’ portfolio include the immunosuppressant Prograf (tacrolimus), the overactive bladder treatments Vesicare (solifenacin) and Myrbetriq (mirabegron), and the prostate cancer therapy Xtandi (enzalutamide).